Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD.
Zonisamide, originally known as an antiepileptic drug, has been approved in Japan as adjunctive therapy with levodopa for the treatment of Parkinson's disease (PD). Although zonisamide reduces neurotoxicity, the precise mechanism of this action is not known. Here, we show that zonisamide increases cell viability in SH-SY5Y cells via an anti-apoptotic effect and by upregulating levels of manganese superoxide dismutase (MnSOD). These results would give us novel evidences of PD treatment.
Kawajiri
Sumihiro
S
Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Machida
Yutaka
Y
Saiki
Shinji
S
Sato
Shigeto
S
Hattori
Nobutaka
N
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D020169:Caspases / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D004298:Dopamine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D020287:In Situ Nick-End Labeling / Q000379:methods; D007555:Isoxazoles / Q000494:pharmacology*; D009447:Neuroblastoma / Q000473:pathology; D009498:Neurotoxins / Q000494:pharmacology; D019311:Staurosporine / Q000494:pharmacology; D013482:Superoxide Dismutase / Q000378:metabolism*; D015854:Up-Regulation / Q000187:drug effects*; D000078305:Zonisamide
D000975:Antioxidants; D004791:Enzyme Inhibitors; D007555:Isoxazoles; D009498:Neurotoxins; D000078305:Zonisamide; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D013482:Superoxide Dismutase; D020169:Caspases; D019311:Staurosporine; D004298:Dopamine